ABBISKO CAYMAN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.58 HKD | +4.68% |
|
+9.15% | -1.92% |
| 04-25 | Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation | MT |
| 04-24 | Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary | CI |
Evolution of the average Target Price on Abbisko Cayman Limited
Price target over the last 5 years
History of analyst recommendation changes
a6a497c2097ac2f44b3bdbd5dbac.m5AGBS6eJizNjSPgzRFMLu3-iKtsPvdg0wK5Gwkd06I.8d9xMV_RSWipzG-6n1odHtzO2M0UYbkOnUWOf2h55tOryStBePJkQ4O1Zg~d1cac4ec73ae446edd5b0dcc170a1b17
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.317
CNY
Average target price
7.572
CNY
Spread / Average Target
+128.29%
High Price Target
14.71
CNY
Spread / Highest target
+343.64%
Low Price Target
3.314
CNY
Spread / Lowest Target
-0.08%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 2256 Stock
- Consensus Abbisko Cayman Limited
